These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 25911848)

  • 1. High frequency of BRAF proto-oncogene hot spot mutation V600E in cohort of colorectal cancer patients from Ahvaz City, southwest Iran.
    Asl JM; Almasi S; Tabatabaiefar MA
    Pak J Biol Sci; 2014 Apr; 17(4):565-9. PubMed ID: 25911848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
    Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
    Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency and application of the hot spot BRAF gene mutation (p.V600E) in the diagnostic strategy for Hereditary Nonpolyposis Colorectal Cancer.
    Kadiyska TK; Konstantinova DV; Atanasov VR; Kremensky IM; Mitev VI
    Cancer Detect Prev; 2007; 31(3):254-6. PubMed ID: 17566669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF mutations in Iranian patients with papillary thyroid carcinoma.
    Ranjbari N; Almasi S; Mohammadi-Asl J; Rahim F
    Asian Pac J Cancer Prev; 2013; 14(4):2521-3. PubMed ID: 23725167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemistry is a feasible method to screen BRAF V600E mutation in colorectal and papillary thyroid carcinoma.
    Zhang X; Wang L; Wang J; Zhao H; Wu J; Liu S; Zhang L; Li Y; Xing X
    Exp Mol Pathol; 2018 Aug; 105(1):153-159. PubMed ID: 30009773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study.
    Taniguchi H; Okamoto W; Muro K; Akagi K; Hara H; Nishina T; Kajiwara T; Denda T; Hironaka S; Kudo T; Satoh T; Yamanaka T; Abe Y; Fukushima Y; Yoshino T
    Neoplasia; 2018 Dec; 20(12):1219-1226. PubMed ID: 30412858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased cancer predisposition in family members of colorectal cancer patients harboring the p.V600E BRAF mutation: a population-based study.
    Wish TA; Hyde AJ; Parfrey PS; Green JS; Younghusband HB; Simms MI; Fontaine DG; Dicks EL; Stuckless SN; Gallinger S; McLaughlin JR; Woods MO; Green RC
    Cancer Epidemiol Biomarkers Prev; 2010 Jul; 19(7):1831-9. PubMed ID: 20570909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant RAS and BRAF mutation in colorectal cancer - A report of 7 cases.
    Ates O; Yalcin S
    Indian J Cancer; 2019; 56(2):176-179. PubMed ID: 31062740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features.
    Roma C; Rachiglio AM; Pasquale R; Fenizia F; Iannaccone A; Tatangelo F; Antinolfi G; Parrella P; Graziano P; Sabatino L; Colantuoni V; Botti G; Maiello E; Normanno N
    Cancer Biol Ther; 2016 Aug; 17(8):840-8. PubMed ID: 27261210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer.
    Osumi H; Shinozaki E; Wakatsuki T; Suenaga M; Ichimura T; Ogura M; Takahari D; Ooki A; Suzuki T; Ota Y; Nakayama I; Chin K; Miki Y; Yamaguchi K
    Int J Cancer; 2019 Nov; 145(9):2488-2495. PubMed ID: 30963570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer.
    Zlobec I; Kovac M; Erzberger P; Molinari F; Bihl MP; Rufle A; Foerster A; Frattini M; Terracciano L; Heinimann K; Lugli A
    Int J Cancer; 2010 Dec; 127(11):2569-75. PubMed ID: 20162668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
    Räsänen K; Dang KX; Mustonen H; Ho TH; Lintula S; Koistinen H; Stenman UH; Haglund C; Stenman J
    Mol Oncol; 2018 Feb; 12(2):224-238. PubMed ID: 29193645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic study of the BRAF gene reveals new variants and high frequency of the V600E mutation among Iranian ameloblastoma patients.
    Soltani M; Tabatabaiefar MA; Mohsenifar Z; Pourreza MR; Moridnia A; Shariati L; Razavi SM
    J Oral Pathol Med; 2018 Jan; 47(1):86-90. PubMed ID: 28650588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demographic trends and KRAS/BRAF
    Fu X; Huang Y; Fan X; Deng Y; Liu H; Zou H; Wu P; Chen Z; Huang J; Wang J; Lin H; Huang S; Tan X; Lan P; Wang L; Wang JP
    Int J Cancer; 2019 May; 144(9):2109-2117. PubMed ID: 30414169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases].
    Gao J; Sun ZW; Li YY; Shen L
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):579-83. PubMed ID: 23157823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oligonucleotide microarray analysis of distinct gene expression patterns in colorectal cancer tissues harboring BRAF and K-ras mutations.
    Kim IJ; Kang HC; Jang SG; Kim K; Ahn SA; Yoon HJ; Yoon SN; Park JG
    Carcinogenesis; 2006 Mar; 27(3):392-404. PubMed ID: 16219636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma.
    Adackapara CA; Sholl LM; Barletta JA; Hornick JL
    Histopathology; 2013 Aug; 63(2):187-93. PubMed ID: 23763264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
    Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation analysis of BRAF exon 15 and KRAS codons 12 and 13 in Moroccan patients with colorectal cancer.
    Bennani B; Gilles S; Fina F; Nanni I; Ibrahimi SA; Riffi AA; Nejjari C; Benajeh DA; El Abkari M; Martin PM; Ouafik L
    Int J Biol Markers; 2010; 25(4):179-84. PubMed ID: 21161938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.